DE602004016499D1 - Zusammensetzungen und verfahren zur behandlung von entzündlicher darmerkrankung - Google Patents
Zusammensetzungen und verfahren zur behandlung von entzündlicher darmerkrankungInfo
- Publication number
- DE602004016499D1 DE602004016499D1 DE602004016499T DE602004016499T DE602004016499D1 DE 602004016499 D1 DE602004016499 D1 DE 602004016499D1 DE 602004016499 T DE602004016499 T DE 602004016499T DE 602004016499 T DE602004016499 T DE 602004016499T DE 602004016499 D1 DE602004016499 D1 DE 602004016499D1
- Authority
- DE
- Germany
- Prior art keywords
- compositions
- type
- interferon
- inflammatory
- endurance
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 230000002757 inflammatory effect Effects 0.000 title 1
- 241000486679 Antitype Species 0.000 abstract 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 2
- 102000014150 Interferons Human genes 0.000 abstract 2
- 108010050904 Interferons Proteins 0.000 abstract 2
- 239000005557 antagonist Substances 0.000 abstract 2
- 229940079322 interferon Drugs 0.000 abstract 2
- 208000015943 Coeliac disease Diseases 0.000 abstract 1
- 206010009900 Colitis ulcerative Diseases 0.000 abstract 1
- 208000011231 Crohn disease Diseases 0.000 abstract 1
- 101000852870 Homo sapiens Interferon alpha/beta receptor 1 Proteins 0.000 abstract 1
- 108010054267 Interferon Receptors Proteins 0.000 abstract 1
- 102000001617 Interferon Receptors Human genes 0.000 abstract 1
- 102100036714 Interferon alpha/beta receptor 1 Human genes 0.000 abstract 1
- 201000006704 Ulcerative Colitis Diseases 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000003993 interaction Effects 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 150000003384 small molecules Chemical class 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US46515503P | 2003-04-23 | 2003-04-23 | |
| PCT/US2004/012651 WO2004093908A2 (en) | 2003-04-23 | 2004-04-23 | Compositions and methods for the therapy of inflammatory bowel disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE602004016499D1 true DE602004016499D1 (de) | 2008-10-23 |
Family
ID=33311000
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE602004016499T Expired - Lifetime DE602004016499D1 (de) | 2003-04-23 | 2004-04-23 | Zusammensetzungen und verfahren zur behandlung von entzündlicher darmerkrankung |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US7939076B2 (de) |
| EP (1) | EP1631312B1 (de) |
| JP (1) | JP4628357B2 (de) |
| KR (1) | KR100817351B1 (de) |
| CN (2) | CN100409897C (de) |
| AT (1) | ATE407698T1 (de) |
| AU (1) | AU2004232362C1 (de) |
| BR (1) | BRPI0410495A (de) |
| CA (2) | CA2823468A1 (de) |
| DE (1) | DE602004016499D1 (de) |
| DK (1) | DK1631312T3 (de) |
| ES (1) | ES2313039T3 (de) |
| HK (1) | HK1082200A1 (de) |
| IL (1) | IL171356A (de) |
| MX (1) | MXPA05011409A (de) |
| NZ (1) | NZ542866A (de) |
| PL (1) | PL1631312T3 (de) |
| PT (1) | PT1631312E (de) |
| SG (1) | SG173919A1 (de) |
| SI (1) | SI1631312T1 (de) |
| WO (1) | WO2004093908A2 (de) |
| ZA (1) | ZA200508390B (de) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ542988A (en) * | 2003-04-23 | 2008-07-31 | Medarex Inc | Humanised antibodies directed against the IFNAR-1 receptor in which murine CDR sequences have been grafted directly into unmodified human framework sequences, resulting in high affinity, functional antibodies |
| WO2004093908A2 (en) | 2003-04-23 | 2004-11-04 | Medarex, Inc. | Compositions and methods for the therapy of inflammatory bowel disease |
| US9107864B2 (en) | 2004-06-07 | 2015-08-18 | Qu Biologics Inc. | Tissue targeted antigenic activation of the immune response to treat cancers |
| US8501198B2 (en) | 2004-06-07 | 2013-08-06 | Qu Biologics Inc. | Tissue targeted antigenic activation of the immune response to treat cancers |
| CA2570823C (en) * | 2004-06-21 | 2015-02-24 | Medarex, Inc. | Interferon alpha receptor 1 antibodies and their uses |
| KR101166901B1 (ko) | 2010-04-16 | 2012-07-19 | 송영완 | 임플란트용 주입기 |
| WO2011153397A2 (en) * | 2010-06-04 | 2011-12-08 | The Brigham And Women's Hospital, Inc. | Treatment of inflammatory disorders |
| NZ606490A (en) | 2010-07-26 | 2015-04-24 | Qu Biolog Inc | Immunogenic anti-inflammatory compositions |
| US8906668B2 (en) | 2012-11-23 | 2014-12-09 | Seres Health, Inc. | Synergistic bacterial compositions and methods of production and use thereof |
| EP3584308A3 (de) | 2013-02-04 | 2020-03-04 | Seres Therapeutics, Inc. | Zusammensetzungen und verfahren |
| EP3904502A3 (de) | 2013-02-04 | 2022-02-23 | Seres Therapeutics, Inc. | Zusammensetzungen und verfahren |
| CA2906921A1 (en) | 2013-03-15 | 2014-09-18 | Seres Therapeutics, Inc. | Network-based microbial compositions and methods |
| MX367109B (es) | 2013-11-25 | 2019-08-05 | Seres Therapeutics Inc | Composiciones bacterianas sinergicas y sus metodos de produccion y usos. |
| EP3082431A4 (de) | 2013-12-16 | 2017-11-15 | Seres Therapeutics, Inc. | Bakterielle zusammensetzungen und verfahren zur verwendung davon zur behandlung von immunsystemkrankheiten |
| RU2724895C2 (ru) | 2014-05-02 | 2020-06-26 | Кью Байолоджикс Инк. | Противомикробная иммуномодуляция |
| US10722468B2 (en) * | 2014-08-14 | 2020-07-28 | Brown University | Compositions for stabilizing and delivering proteins |
| US11097005B2 (en) | 2014-12-15 | 2021-08-24 | The Brigham And Women's Hospital, Inc. | Use of cadherin-11 antagonists to treat metabolic disorders and/or increase insulin sensitivity |
| CN107074943B (zh) | 2016-07-14 | 2018-08-24 | 中国科学院生物物理研究所 | I型干扰素受体抗体及其用途 |
| US20230149497A1 (en) * | 2017-06-02 | 2023-05-18 | Goodgut S.L. | Grape skin for use in the treatment of dysbiosis |
| JP2020530840A (ja) | 2017-08-14 | 2020-10-29 | セレス セラピューティクス インコーポレイテッド | 胆汁うっ滞性疾患を治療するための組成物及び方法 |
| SG11202001311VA (en) | 2017-08-22 | 2020-03-30 | Sanabio Llc | Soluble interferon receptors and uses thereof |
| CN112056275B (zh) * | 2020-09-27 | 2022-05-10 | 澎立生物医药技术（上海）有限公司 | 一种肠粘膜炎动物模型及其构建方法和应用 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5516515A (en) * | 1986-02-05 | 1996-05-14 | Interferon Sciences, Inc. | Separation of alpha interferon receptor proteins and antibodies therefor |
| IL78444A (en) * | 1986-04-08 | 1992-05-25 | Yeda Res & Dev | Human gamma interferon-specific receptor protein,antibody against said protein,and compositions containing said protein and antibody |
| IL88377A (en) | 1988-11-14 | 1996-09-12 | Yeda Res & Dev | Cloning and expression of a protein which modulates cellular response to type I interferon |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5889151A (en) * | 1989-10-20 | 1999-03-30 | Societe Leb-Tech | Purified human alpha interferon receptor |
| FR2653445B1 (fr) | 1989-10-20 | 1994-07-29 | Centre Nat Rech Scient | Fragment d'adnc codant pour le gene du recepteur de l'interferon alpha et procede de preparation d'une proteine correspondante. |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
| WO1993004699A1 (en) | 1991-08-30 | 1993-03-18 | Genentech, Inc. | Therapeutic method for iddm |
| EP0563487A1 (de) * | 1992-03-31 | 1993-10-06 | Laboratoire Europeen De Biotechnologie S.A. | Monoklonale Antikörper gegen den Interferonrezeptor, mit neutralisierender Aktivität gegen Typ I-Interferon |
| US5821078A (en) * | 1992-09-03 | 1998-10-13 | Yeda Research And Development Co. Ltd. | Nucleic acid encoding interferon-α/β binding protein |
| ATE173630T1 (de) * | 1992-12-29 | 1998-12-15 | Genentech Inc | Behandlung von entzündlichen darmerkrankungen mit interferon-gamma-inhibitoren |
| US5888511A (en) * | 1993-02-26 | 1999-03-30 | Advanced Biotherapy Concepts, Inc. | Treatment of autoimmune diseases, including AIDS |
| WO1995007716A1 (en) * | 1993-09-17 | 1995-03-23 | Laboratoire Europeen De Biotechnologie S.A. | Pharmaceutical composition comprising monoclonal antibodies against the interferon receptor, with neutralizing activity against type i interferon |
| AU1289595A (en) | 1993-11-15 | 1995-06-06 | Cell Therapeutics, Inc. | Method for selectively inhibiting il-2 signal transduction |
| US7285526B2 (en) * | 1995-07-14 | 2007-10-23 | Meiogen Biotechnology Corporation | Interferon antagonists useful for the treatment of interferon related diseases |
| IL118096A0 (en) * | 1996-05-01 | 1996-09-12 | Yeda Res & Dev | Antibodies against interferon alpha/beta receptor |
| US6713609B1 (en) * | 1996-07-16 | 2004-03-30 | Genentech, Inc. | Monoclonal antibodies to type I interferon receptor |
| EP1724282B1 (de) | 1997-05-21 | 2013-05-15 | Merck Patent GmbH | Verfahren zur Herstellung von nicht-immunogenen Proteinen |
| FR2769505B1 (fr) | 1997-10-10 | 2000-06-30 | Michael Gerard Tovey | Compositions de cytokines a administrer a la muqueuse buccale, et leurs utilisations |
| US6238925B1 (en) * | 1998-01-30 | 2001-05-29 | Panacea Pharmaceuticals, Llc | Method for determining likelihood of developing clinical tolerance |
| AUPP670698A0 (en) | 1998-10-23 | 1998-11-19 | Monash University | A method of regulation |
| US6329159B1 (en) | 1999-03-11 | 2001-12-11 | Millennium Pharmaceuticals, Inc. | Anti-GPR-9-6 antibodies and methods of identifying agents which modulate GPR-9-6 function |
| MXPA02000962A (es) | 1999-07-29 | 2002-07-02 | Medarex Inc | Anticuerpos monoclonales humanos para her2/neu. |
| EP2829609A1 (de) | 1999-08-24 | 2015-01-28 | E. R. Squibb & Sons, L.L.C. | Humane Antikörper gegen CTLA-4-Antikörper und Verwendungen davon |
| US6264981B1 (en) * | 1999-10-27 | 2001-07-24 | Anesta Corporation | Oral transmucosal drug dosage using solid solution |
| GB0001712D0 (en) * | 2000-01-25 | 2000-03-15 | Pharma Pacific Pty Ltd | Therapeutic peptides |
| GB0001710D0 (en) | 2000-01-25 | 2000-03-15 | Pharma Pacific Pty Ltd | Therapeutic treatment |
| JP3523245B1 (ja) | 2000-11-30 | 2004-04-26 | メダレックス，インコーポレーテッド | ヒト抗体作製用トランスジェニック染色体導入齧歯動物 |
| US7087726B2 (en) * | 2001-02-22 | 2006-08-08 | Genentech, Inc. | Anti-interferon-α antibodies |
| JP4156324B2 (ja) | 2002-09-30 | 2008-09-24 | ローム株式会社 | 直流−交流変換装置、及び交流電力供給方法 |
| WO2004093908A2 (en) | 2003-04-23 | 2004-11-04 | Medarex, Inc. | Compositions and methods for the therapy of inflammatory bowel disease |
| NZ542988A (en) | 2003-04-23 | 2008-07-31 | Medarex Inc | Humanised antibodies directed against the IFNAR-1 receptor in which murine CDR sequences have been grafted directly into unmodified human framework sequences, resulting in high affinity, functional antibodies |
| CA2546054C (en) * | 2003-12-10 | 2014-05-13 | Medarex, Inc. | Interferon alpha antibodies and their uses |
| CA2570823C (en) * | 2004-06-21 | 2015-02-24 | Medarex, Inc. | Interferon alpha receptor 1 antibodies and their uses |
-
2004
- 2004-04-23 WO PCT/US2004/012651 patent/WO2004093908A2/en active Application Filing
- 2004-04-23 DE DE602004016499T patent/DE602004016499D1/de not_active Expired - Lifetime
- 2004-04-23 KR KR1020057020211A patent/KR100817351B1/ko not_active IP Right Cessation
- 2004-04-23 ES ES04750581T patent/ES2313039T3/es not_active Expired - Lifetime
- 2004-04-23 CA CA2823468A patent/CA2823468A1/en not_active Abandoned
- 2004-04-23 US US10/831,432 patent/US7939076B2/en not_active Expired - Fee Related
- 2004-04-23 BR BRPI0410495-1A patent/BRPI0410495A/pt not_active Application Discontinuation
- 2004-04-23 SG SG2007007115A patent/SG173919A1/en unknown
- 2004-04-23 NZ NZ542866A patent/NZ542866A/xx not_active IP Right Cessation
- 2004-04-23 SI SI200430937T patent/SI1631312T1/sl unknown
- 2004-04-23 CN CNB2004800105953A patent/CN100409897C/zh not_active Expired - Fee Related
- 2004-04-23 PT PT04750581T patent/PT1631312E/pt unknown
- 2004-04-23 AU AU2004232362A patent/AU2004232362C1/en not_active Ceased
- 2004-04-23 MX MXPA05011409A patent/MXPA05011409A/es active IP Right Grant
- 2004-04-23 CA CA2522957A patent/CA2522957C/en not_active Expired - Fee Related
- 2004-04-23 DK DK04750581T patent/DK1631312T3/da active
- 2004-04-23 JP JP2006513278A patent/JP4628357B2/ja not_active Expired - Fee Related
- 2004-04-23 EP EP04750581A patent/EP1631312B1/de not_active Expired - Lifetime
- 2004-04-23 CN CN2008101102238A patent/CN101318019B/zh not_active Expired - Fee Related
- 2004-04-23 PL PL04750581T patent/PL1631312T3/pl unknown
- 2004-04-23 AT AT04750581T patent/ATE407698T1/de active
-
2005
- 2005-10-10 IL IL171356A patent/IL171356A/en not_active IP Right Cessation
- 2005-10-17 ZA ZA200508390A patent/ZA200508390B/xx unknown
-
2006
- 2006-03-20 HK HK06103497.6A patent/HK1082200A1/xx not_active IP Right Cessation
-
2011
- 2011-03-17 US US13/050,601 patent/US8828393B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE602004016499D1 (de) | Zusammensetzungen und verfahren zur behandlung von entzündlicher darmerkrankung | |
| DE60142614D1 (de) | Inität | |
| DK3530673T3 (da) | Humaniserede anti-beta7-antagonister og anvendelser deraf | |
| NO20072721L (no) | Polypeptides that bind BR3 and uses thereof | |
| ATE509953T1 (de) | Antikörper gegen den erythropoietinrezeptor und verwendungen davon | |
| EA200601555A1 (ru) | Замещенные индазол-о-глюкозиды | |
| DE60229059D1 (de) | Proteomimetische verbindungen und verfahren | |
| ATE310955T1 (de) | Zusammensetzungen und verfahren zum nachweis und zur behandlung von mit chemokinrezeptoren verbundenen krankheiten | |
| TW200738748A (en) | Human monoclonal antibody human CD134 (OX40) and methods of making and using same | |
| RS52769B (sr) | Kompozicije i postupci za povećanje mineralizacije kostiju | |
| EA200602062A1 (ru) | Амидосоединения и их применение в качестве фармацевтических средств | |
| ATE387435T1 (de) | Substituirte benzosulfonamide als potenzierungsmittel von glutamatrezeptoren | |
| DK1409544T3 (da) | Humane DR4-antistoffer og anvendelser deraf | |
| ATE517920T1 (de) | Humanisierte antikörper gegen interferon-alpha- rezeptor-1 (ifnar-1) | |
| ATE543833T1 (de) | Bmp-7-varianten-zusammensetzungen, verfahren und verwendungen | |
| EA200601220A1 (ru) | Анти-trkc антитела-агонисты и способы их применения | |
| MXPA05011085A (es) | Composiciones y metodos relacionados a stop-1. | |
| MXPA05007940A (es) | Composiciones y metodos para el tratamiento del cancer usando igsf9 y liv-1. | |
| DK1234025T3 (da) | Humane enzymer fra metalloproteasefamilien | |
| DE60024997D1 (de) | Vgf polypeptide und verfahren zur behandlung von vgf-erkrankungen | |
| ATE402958T1 (de) | Antagonisten des ige-rezeptors | |
| DE602005013287D1 (de) | Zusammensetzung zur behandlung von leder | |
| ATE533500T1 (de) | Hemmer der antigenpräsentation über mhc-klasse-ii-moleküle und verwendungsverfahren dafür | |
| ATE420162T1 (de) | Verfahren und zusammensetzungen zum targeting sekretorischer lysosomen | |
| FR2873037B1 (fr) | Methodes et compositions pour le traitement de cancers |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |